2021
Diverse functional autoantibodies in patients with COVID-19
Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, Liu F, Zhou T, Israelow B, Wong P, Coppi A, Lucas C, Silva J, Oh JE, Song E, Perotti ES, Zheng NS, Fischer S, Campbell M, Fournier JB, Wyllie AL, Vogels CBF, Ott IM, Kalinich CC, Petrone ME, Watkins AE, Dela Cruz C, Farhadian S, Schulz W, Ma S, Grubaugh N, Ko A, Iwasaki A, Ring A. Diverse functional autoantibodies in patients with COVID-19. Nature 2021, 595: 283-288. PMID: 34010947, DOI: 10.1038/s41586-021-03631-y.Peer-Reviewed Original ResearchConceptsPeripheral immune cell compositionSARS-CoV-2 infectionCOVID-19Effects of autoantibodiesTissue-associated antigensSpecific clinical characteristicsInnate immune activationImmune cell compositionCOVID-19 exhibitCOVID-19 manifestsAnalysis of autoantibodiesSARS-CoV-2Functional autoantibodiesMouse surrogateClinical characteristicsVirological controlClinical outcomesImmune activationMild diseaseAsymptomatic infectionAutoantibody reactivityDisease progressionHealthcare workersHigh prevalenceAutoantibodiesEarly introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States
Alpert T, Brito AF, Lasek-Nesselquist E, Rothman J, Valesano AL, MacKay MJ, Petrone ME, Breban MI, Watkins AE, Vogels CBF, Kalinich CC, Dellicour S, Russell A, Kelly JP, Shudt M, Plitnick J, Schneider E, Fitzsimmons WJ, Khullar G, Metti J, Dudley JT, Nash M, Beaubier N, Wang J, Liu C, Hui P, Muyombwe A, Downing R, Razeq J, Bart SM, Grills A, Morrison SM, Murphy S, Neal C, Laszlo E, Rennert H, Cushing M, Westblade L, Velu P, Craney A, Cong L, Peaper DR, Landry ML, Cook PW, Fauver JR, Mason CE, Lauring AS, St George K, MacCannell DR, Grubaugh ND. Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States. Cell 2021, 184: 2595-2604.e13. PMID: 33891875, PMCID: PMC8018830, DOI: 10.1016/j.cell.2021.03.061.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 lineage B.1.1.7SARS-CoV-2 variant B.1.1.7Global public health concernPublic health concernPublic health responseCOVID-19 casesLineage B.1.1.7Variant B.1.1.7Health responseHealth concernB.1.1.7Increased transmissibilityEarly introductionGenomic surveillanceUnited StatesDiagnostic dataDominant lineageAsynchronicity of endemic and emerging mosquito-borne disease outbreaks in the Dominican Republic
Petrone ME, Earnest R, Lourenço J, Kraemer MUG, Paulino-Ramirez R, Grubaugh ND, Tapia L. Asynchronicity of endemic and emerging mosquito-borne disease outbreaks in the Dominican Republic. Nature Communications 2021, 12: 151. PMID: 33420058, PMCID: PMC7794562, DOI: 10.1038/s41467-020-20391-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAedesAnimalsChikungunya FeverChikungunya virusChildChild, PreschoolCommunicable Diseases, EmergingDengueDengue VirusDisease OutbreaksDominican RepublicEndemic DiseasesEpidemiological MonitoringFemaleHumansInfantInfant, NewbornMaleMosquito ControlMosquito VectorsSpatio-Temporal AnalysisYoung AdultZika VirusZika Virus InfectionConceptsDengue outbreakDisease outbreaksDengue fever casesOutbreak of chikungunyaMosquito-Borne VirusesFever casesFuture health crisesMosquito-borne disease outbreaksFuture outbreaksVirus transmissionAedes mosquitoesSustainable disease control measuresHealth crisisVirusDisease control measuresOutbreakChikungunyaConstant surveillanceZikaControl measuresDominican Republic
2016
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Bar KJ, Sneller MC, Harrison LJ, Justement JS, Overton ET, Petrone ME, Salantes DB, Seamon CA, Scheinfeld B, Kwan RW, Learn GH, Proschan MA, Kreider EF, Blazkova J, Bardsley M, Refsland EW, Messer M, Clarridge KE, Tustin NB, Madden PJ, Oden K, O'Dell SJ, Jarocki B, Shiakolas AR, Tressler RL, Doria-Rose NA, Bailer RT, Ledgerwood JE, Capparelli EV, Lynch RM, Graham BS, Moir S, Koup RA, Mascola JR, Hoxie JA, Fauci AS, Tebas P, Chun TW. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. New England Journal Of Medicine 2016, 375: 2037-2050. PMID: 27959728, PMCID: PMC5292134, DOI: 10.1056/nejmoa1608243.Peer-Reviewed Original ResearchConceptsPlasma viral reboundHuman immunodeficiency virusAntiretroviral therapyViral reboundViral suppressionHIV infectionPassive immunizationHistorical controlsWeek 8Interruption of ARTNeutralization-resistant virusesOpen-label trialSide effect profileART interruptionSingle bNAbsTreatment interruptionAdverse eventsMedian timeImmunodeficiency virusNIH trialPassive administrationHIV CD4Week 4Antibody VRC01Trial participants